Logo image of ITRM

ITERUM THERAPEUTICS PLC (ITRM) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ITRM - IE000TTOOBX0 - Common Stock

0.2881 USD
0 (-0.31%)
Last: 12/30/2025, 8:00:03 PM
0.291 USD
+0 (+1.01%)
After Hours: 12/30/2025, 8:00:03 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to ITRM. ITRM was compared to 191 industry peers in the Pharmaceuticals industry. ITRM may be in some trouble as it scores bad on both profitability and health. ITRM has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ITRM has reported negative net income.
ITRM had a negative operating cash flow in the past year.
In the past 5 years ITRM always reported negative net income.
In the past 5 years ITRM always reported negative operating cash flow.
ITRM Yearly Net Income VS EBIT VS OCF VS FCFITRM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

ITRM has a worse Return On Assets (-82.95%) than 76.44% of its industry peers.
Industry RankSector Rank
ROA -82.95%
ROE N/A
ROIC N/A
ROA(3y)-89.08%
ROA(5y)-105.18%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ITRM Yearly ROA, ROE, ROICITRM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 -400 600

1.3 Margins

ITRM does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ITRM Yearly Profit, Operating, Gross MarginsITRM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50K -100K -150K -200K -250K

More info and screens

2

2. Health

2.1 Basic Checks

Compared to 1 year ago, ITRM has more shares outstanding
Compared to 5 years ago, ITRM has more shares outstanding
The debt/assets ratio for ITRM is higher compared to a year ago.
ITRM Yearly Shares OutstandingITRM Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
ITRM Yearly Total Debt VS Total AssetsITRM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

ITRM has an Altman-Z score of -23.40. This is a bad value and indicates that ITRM is not financially healthy and even has some risk of bankruptcy.
ITRM has a worse Altman-Z score (-23.40) than 86.91% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -23.4
ROIC/WACCN/A
WACCN/A
ITRM Yearly LT Debt VS Equity VS FCFITRM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

2.3 Liquidity

A Current Ratio of 2.13 indicates that ITRM has no problem at all paying its short term obligations.
The Current ratio of ITRM (2.13) is comparable to the rest of the industry.
ITRM has a Quick Ratio of 1.96. This is a normal value and indicates that ITRM is financially healthy and should not expect problems in meeting its short term obligations.
ITRM has a Quick ratio of 1.96. This is comparable to the rest of the industry: ITRM outperforms 43.46% of its industry peers.
Industry RankSector Rank
Current Ratio 2.13
Quick Ratio 1.96
ITRM Yearly Current Assets VS Current LiabilitesITRM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

1

3. Growth

3.1 Past

ITRM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 63.50%, which is quite impressive.
EPS 1Y (TTM)63.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ITRM will show a very strong growth in Earnings Per Share. The EPS will grow by 23.81% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y58.09%
EPS Next 2Y34.1%
EPS Next 3Y27.71%
EPS Next 5Y23.81%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ITRM Yearly Revenue VS EstimatesITRM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M
ITRM Yearly EPS VS EstimatesITRM Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 -50 -100

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ITRM. In the last year negative earnings were reported.
Also next year ITRM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ITRM Price Earnings VS Forward Price EarningsITRM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ITRM Per share dataITRM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6

4.3 Compensation for Growth

A more expensive valuation may be justified as ITRM's earnings are expected to grow with 27.71% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.1%
EPS Next 3Y27.71%

More info and screens

0

5. Dividend

5.1 Amount

ITRM does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

ITERUM THERAPEUTICS PLC

NASDAQ:ITRM (12/30/2025, 8:00:03 PM)

After market: 0.291 +0 (+1.01%)

0.2881

0 (-0.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-14 2025-11-14/bmo
Earnings (Next)02-05 2026-02-05/amc
Inst Owners2.56%
Inst Owner Change-43.41%
Ins Owners0.79%
Ins Owner Change0.41%
Market Cap15.21M
Revenue(TTM)390.00K
Net Income(TTM)-26.96M
Analysts82.5
Price Target5.61 (1847.24%)
Short Float %3.36%
Short Ratio1.83
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-60.43%
Min EPS beat(2)-78.25%
Max EPS beat(2)-42.6%
EPS beat(4)1
Avg EPS beat(4)-30.1%
Min EPS beat(4)-78.25%
Max EPS beat(4)5.34%
EPS beat(8)4
Avg EPS beat(8)-11.7%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-21.43%
PT rev (3m)-21.43%
EPS NQ rev (1m)-46.15%
EPS NQ rev (3m)-46.15%
EPS NY rev (1m)-21.84%
EPS NY rev (3m)-21.84%
Revenue NQ rev (1m)7.32%
Revenue NQ rev (3m)7.32%
Revenue NY rev (1m)14.29%
Revenue NY rev (3m)14.29%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 39
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.73
EYN/A
EPS(NY)-0.26
Fwd EYN/A
FCF(TTM)-0.36
FCFYN/A
OCF(TTM)-0.36
OCFYN/A
SpS0.01
BVpS-0.14
TBVpS-0.49
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -82.95%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-89.08%
ROA(5y)-105.18%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.21%
Cap/Sales 4.1%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.13
Quick Ratio 1.96
Altman-Z -23.4
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)1.59%
Cap/Depr(5y)2.78%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)63.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
EPS Next Y58.09%
EPS Next 2Y34.1%
EPS Next 3Y27.71%
EPS Next 5Y23.81%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-24.25%
EBIT Next 3Y47.86%
EBIT Next 5YN/A
FCF growth 1Y38.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y38.12%
OCF growth 3YN/A
OCF growth 5YN/A

ITERUM THERAPEUTICS PLC / ITRM FAQ

What is the ChartMill fundamental rating of ITERUM THERAPEUTICS PLC (ITRM) stock?

ChartMill assigns a fundamental rating of 1 / 10 to ITRM.


Can you provide the valuation status for ITERUM THERAPEUTICS PLC?

ChartMill assigns a valuation rating of 1 / 10 to ITERUM THERAPEUTICS PLC (ITRM). This can be considered as Overvalued.


What is the profitability of ITRM stock?

ITERUM THERAPEUTICS PLC (ITRM) has a profitability rating of 0 / 10.